Among these, TNF-α inhibitors, such as etanercept and adalimumab, which are commonly used in autoimmune diseases, are currently under evaluation in clinical trials for conditions like multiple sclerosis (MS) and AD due to their potential to reduce BBB leakage and protect neuronal tissue [359]. The gene discussed is TNF; the disease is Alzheimer disease.